Awny Farajallah

868 total citations
12 papers, 649 citations indexed

About

Awny Farajallah is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Awny Farajallah has authored 12 papers receiving a total of 649 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 9 papers in Virology and 5 papers in Emergency Medicine. Recurrent topics in Awny Farajallah's work include HIV/AIDS drug development and treatment (11 papers), HIV Research and Treatment (9 papers) and HIV/AIDS Research and Interventions (8 papers). Awny Farajallah is often cited by papers focused on HIV/AIDS drug development and treatment (11 papers), HIV Research and Treatment (9 papers) and HIV/AIDS Research and Interventions (8 papers). Awny Farajallah collaborates with scholars based in United States, Germany and United Kingdom. Awny Farajallah's co-authors include Ann C. Collier, William C. Woodward, Katie R. Mollan, David Katzenstein, Margaret A. Fischl, Paul E. Sax, Belinda Ha, James F. Rooney, Catherine Godfrey and Edwin DeJesus and has published in prestigious journals such as New England Journal of Medicine, The Journal of Infectious Diseases and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Awny Farajallah

11 papers receiving 627 citations

Peers

Awny Farajallah
Fredy Suter Italy
Miguel Goicoechea United States
Martin Gartland United Kingdom
Christiane Moecklinghoff Germany
Marie-Aude Khuong-Josses France
Melcior Riera Spain
Ya-Pei Liu United States
Kati Vandermeulen Belgium
David Shamblaw United States
Naomi Givens United Kingdom
Fredy Suter Italy
Awny Farajallah
Citations per year, relative to Awny Farajallah Awny Farajallah (= 1×) peers Fredy Suter

Countries citing papers authored by Awny Farajallah

Since Specialization
Citations

This map shows the geographic impact of Awny Farajallah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Awny Farajallah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Awny Farajallah more than expected).

Fields of papers citing papers by Awny Farajallah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Awny Farajallah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Awny Farajallah. The network helps show where Awny Farajallah may publish in the future.

Co-authorship network of co-authors of Awny Farajallah

This figure shows the co-authorship network connecting the top 25 collaborators of Awny Farajallah. A scholar is included among the top collaborators of Awny Farajallah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Awny Farajallah. Awny Farajallah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
3.
McDonald, Cheryl, Jonathan Uy, Wenhua Hu, et al.. (2012). Clinical Significance of Hyperbilirubinemia Among HIV-1–Infected Patients Treated with Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study. AIDS Patient Care and STDs. 26(5). 259–264. 25 indexed citations
4.
Kozal, Michael J., Sergio Lupo, Edwin DeJesus, et al.. (2012). A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results. HIV Clinical Trials. 13(3). 119–130. 70 indexed citations
5.
Sax, Paul E., Camlin Tierney, Ann C. Collier, et al.. (2011). Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results. The Journal of Infectious Diseases. 204(8). 1191–1201. 130 indexed citations
6.
7.
Hodder, Sally, Karam Mounzer, Edwin DeJesus, et al.. (2010). Patient-Reported Outcomes in Virologically Suppressed, HIV-1–Infected Subjects After Switching to a Simplified, Single-Tablet Regimen of Efavirenz, Emtricitabine, and Tenofovir DF. AIDS Patient Care and STDs. 24(2). 87–96. 67 indexed citations
8.
Uy, J., et al.. (2010). Clinical significance of hyperbilirubinemia in the CASTLE study. Journal of the International AIDS Society. 13(S4). 3 indexed citations
9.
DeJesus, Edwin, Benjamin Young, Javier O Morales-Ramirez, et al.. (2009). Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 51(2). 163–174. 108 indexed citations
10.
Sax, Paul E., Camlin Tierney, Ann C. Collier, et al.. (2009). Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy. New England Journal of Medicine. 361(23). 2230–2240. 215 indexed citations
11.
Uy, J., et al.. (2008). Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated With atazanavir/r and lopinavir/r in the CASTLE study. Journal of the International AIDS Society. 11(Suppl 1). P8–P8. 7 indexed citations
12.
Hodder, Sally, et al.. (2008). Patient-reported outcomes after simplification to a single tablet regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir DF (TDF). Journal of the International AIDS Society. 11(Suppl 1). P63–P63. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fredy Suter Breakdown of academic impact, for papers by Miguel Goicoechea Breakdown of academic impact, for papers by Martin Gartland Breakdown of academic impact, for papers by Christiane Moecklinghoff Breakdown of academic impact, for papers by Marie-Aude Khuong-Josses Breakdown of academic impact, for papers by Melcior Riera Breakdown of academic impact, for papers by Ya-Pei Liu Breakdown of academic impact, for papers by Kati Vandermeulen Breakdown of academic impact, for papers by David Shamblaw Breakdown of academic impact, for papers by Naomi Givens
Rankless by CCL
2026